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Purpose: The purpose of this research was to evaluate the feasibility of sentinel lymph node (SLN) mapping involving trans-
anal injection with an ex-vivo mapping in patients with rectal cancer.
Methods: Between April 2007 and December 2009, 20 consecutive patients with T1-3, N0-1 clinical stage rectal cancer pre-
operatively underwent a SLN procedure using submucosal 
99mTc-phytate injection. All the patients underwent a total me-
sorectal excision. After the standard surgical resection, all specimens were identified on lymphoscintigraphy, and bench work 
was done to pick up the sentinel node basin. All the lymph nodes (non-SLNs and SLNs) were examined using conventional 
hematoxylin and eosin staining and immunohistochemistry with anti-cytokeratin antibodies.
Results: SLNs were identified from 19 of 20 patients with rectal cancer. The total number of sentinel nodes retrieved from 
the surgical specimens was 29, and the mean number per patient was 1.6 (range, 0 to 4). In three patients, the SLN was the 
only positive lymph node. There was one false-negative case with a sensitivity of 88.8% and two upstaged cases (20.0%). The 
SLN samples from rectal cancer are mainly localized in the pararectal region, but aberrant nodes receive direct drainage 
from the rectal cancer. On planar lymphoscintigraphy, 15.7% of all patients had aberrant lymphatic drainage to the sigmoid 
mesenteric or sigmoid lymph node station.
Conclusion: In conclusion, the intraoperative transanal injection for ex-vivo SLN navigation is a safe, feasible surgical mo-
dality in patients with rectal cancer. Large studies are warranted to determine the clinical significance of the SLN concept 
and micrometastasis in rectal cancer.
Keywords: Rectal neoplasms; Transanal injection; Sentinel lymph node; Lymphoscintigraphy  
improvement in survival with the use of adjuvant chemotherapy 
[1]. In patients with node-negative disease, however, the benefit of 
adjuvant chemotherapy remains controversial although the recur-
rence and the mortality have been reported to reach 30% [2, 3]. 
Relapse is presumed to occur in patients who have lymph node 
metastasis that has not identified by conventional histopathologic 
examination.
The term “sentinel node” was coined in 1977 by Cabanas [4] in 
his study of penile carcinomas. Nowadays, sentinel lymph node 
(SLN) mapping is the standard nodal staging technique in patients 
with breast cancer. The advantage of this technique is that there is 
no potentially harmful auxiliary dissection. In patients with colorec-
tal cancer, this is not an issue. Thus, the benefit of SLN mapping 
has to be found in fact that with this technique, potentially high-
risk patients, who could develop metastases in time, can be iden-
INTRODUCTION
Lymph node involvement is one of the most important prognos-
tic factors in the evaluation of colorectal cancer. Randomized tri-
als have demonstrated a 40% reduction in recurrence and a 33% 
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tified and, maybe, benefit from adjuvant therapy (upstaging to 
node positive level). In the majority of patients, the importance of 
SLN mapping will rest in this technique’s ability to more accurately 
identify the node most likely to harbor metastasis and allow fo-
cused evaluation of that node. Focused evaluation will result in 
more precise prognostic information and will identify a group of 
patients who can likely benefit from adjuvant treatment. A num-
ber of studies have investigated the SLN mapping technique and 
have described successful SLN identification in colorectal cancer, 
with identification rates of 94-100% and upstaging ranging from 
20 to 30% [5-7].
The optimal method for detecting the SLNs in patients with 
colorectal cancer remains controversial, and several methods, in-
cluding blue dye, lymphoscintigraphy using radiocolloids, and por-
table gamma cameras or near-infrared fluorescence light, have 
been described [8]. In the majority of published studies of SLN 
mapping in the treatment of colorectal cancer, subserosal in-vivo 
injection of visible dye (i.e., methylene blue or isosulfan blue) and 
intraoperative identification were used. Although promising re-
sults would be expected in the colon cancer with this technique, it 
might be less applicable for rectal cancer than for colon cancer. 
Because the rectum is anatomically quite different from the colon, 
with a bulkier and infraperitoneal location, the conventional pro-
cedure (intraopertive, subserosal, and circumferential injection) is 
more difficult in the rectum. The aim of this study was to evaluate 
the feasibility of SLN mapping based on a combination of injec-
tion of a radioisotope prior to rectal dissection and ex-vivo SLN 
mapping in patients with rectal cancer and its potential applica-
tion in practice.
METHODS
From May 2009 to December 2010, the prospectively collected 
records of 20 consecutive rectal cancer patients with T1-3, N0-1 
clinical stage cancer were reviewed retrospectively. Preoperative 
evaluation included colonoscopy, abdominal computed tomogra-
phy, magnetic resonance imaging, and blood test. Patients with 
rectal cancer located intraperitoneally (above peritoneal reflection), 
lateral node involvement confirmed by an imaging study, tumor 
invasion of an adjacent organ (T4), and distant metastasis and pa-
tients refusing to participate were not included in the study.
In the current study, the primary endpoints (outcome measures) 
are the detection rate and the sensitivity of SLN mapping in the 
treatment of rectal cancer, and the secondary endpoint (outcome 
measure) is the upstaging rate of an ex-vivo approach and assess-
ment of the aberrant lymphatic drainage pattern. Patient recruit-
ment and sample collection were performed in accordance with 
the protocol guidelines of the Institutional Review Board (IRB) of 
our institution, and all patients included in this study submitted a 
written informed consent.
The SLN procedure is illustrated in Fig. 1. 
99mTc-phytate agent 
(0.5-1.0 mL, 1.0 mCi, non-filtered) was intraoperatively injected 
into the rectal submucosa transanally. Immediately after general 
anesthesia and subsequent positioning, the investigator used a 
Park’s anal retractor and a 25-gauge spinal needle to inject a radio-
active contrast medium into the areas adjacent to the tumor at two 
to four points, depending on the size of the tumor. After submu-
cosal injection, all patients underwent a standard total mesorectal 
excision, and this included the total mesocolon of the correspond-
ing vascular trunk. After standard surgical resection, all specimens 
were identified by using lymphoscintigraphy. The location and the 
number of sentinel nodes were recorded. Following an imaging 
study, bench work was done at a separate back table to pick up the 
sentinel basin (Fig. 2). All nodal areas were localized with a hand-
held gamma probe (Neo 2000; Neoprobe, Dublin, OH, USA) to 
confirm the radiation “hot spots,” which had already been identi-
fied on lymphoscintigraphy. A lymph node was considered to be 
a sentinel node when it showed ex-vivo radioactive counts tenfold 
higher than the background radioactivity. An SLN mapping was 
generally performed within four hours, but no later than eight 
hours after the specimen retrieval.
All excised SLNs were sent to the Pathology Department sepa-
rately from other materials and were examined in detail. After har-
vesting, two different senior pathologists examined the specimens 
and lymph nodes by using a standard pathologic method. If the 
SLNs were negative after routine H&E staining, they were sectioned 
at 150-μm intervals and examined at four or five levels by H&E 
staining and by immunohistochemistry using a pan-cytokeratin 
antibody (1:50, mouse antihuman cytokeratin monoclonal anti-
body, clone AE1/AE3, IgG1-kappa, M3515; DakoCytomation, 
Carpinteria, CA, USA). The remaining non-SLNs underwent an 
identical histopathological workup and were examined with serial 
Pathological examination of entire lymph nodes 
(H&E, IHC): validation of sentinel node mapping
Intra-operative transanal submucosal injection of 
99mTc-phytate (1.0 mCi, 0.5-1.0 mL)
Standard radical surgery
Ex-vivo lymphoscintigraphy Check of remnant RI  
with gamma probe
Sentinel node extirpation  
on the back table
Fig. 1. Protocol of sentinel node mapping. Intraoperative 
99mTc-phy-
tate was injected into the rectal submucosa. 
RI, radioisotope; H&E, hematoxylin and eosin staining; IHC, immu-
nohistochemistry.Journal of The Korean Society of
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section H&E staining and cytokeratin immunohistochemical stain-
ing.
We classified lymph nodes according to the Japanese classifica-
tion of colorectal carcinoma. The Japanese criteria define the nodes 
at the origin of the inferior mesenteric artery (IMA; station 253) 
as those that lie along the IMA proximal to the origin of the left 
colic artery. They define the inferior mesenteric trunk nodes (sta-
tion 252) as those that lie along the IMA from distal to the origin 
of the left colic artery to the bifurcation of the superior rectal ar-
tery and the pararectal nodes (station 251) as those that lie along 
the superior rectal artery. They are categorized as sigmoid nodes 
(station 242) when they are located along the sigmoid artery be-
tween the IMA and the marginal artery and as sigmoid mesenteric 
nodes (station 241) when they are located along the marginal ar-
tery between the superior rectal artery and the proximal margin.
In this study, metastases between 0.2 and 2 mm are referred to as 
micrometastases, and metastases smaller than 0.2 mm are referred 
to as isolated tumor cells. Upstaging is defined as the presence of 
micrometastases or isolated tumor cells found by using immuno-
histochemistry for patients with a negative lymph node status after 
conventional H&E staining. Only descriptive statistics are used.
RESULTS
The 20 consecutive patients with rectal cancer who underwent 
curative total mesonectal excision (TME) between May 2009 and 
December 2010 were prospectively enrolled. All these patients had 
no radiologically diagnosed lateral pelvic lymph node metastasis. 
The median age was 64 years (range, 47 to 80 years), and the ratio 
of men to women was 10:10. The mean distance from the anal 
verge was 6.5 cm (range, 3 to 9 cm). The mean tumor size was 3.5 
cm (range, 1.0 to 5.5 cm). Tumor features are summarized in Ta-
ble 1. Seven patients with low rectal cancer underwent an inter-
sphincteric resection with coloanal anastomosis. Seven of the 20 
patients received neo-adjuvant radio-chemotherapy (50 Gy in 25 
fractions for five weeks).
In all cases but one, lymphatic flow was visualized on the lym-
phoscintigraphy (detection rate, 95.0%) (Table 2). An example of 
lymphoscintigraphy of an ex-vivo specimen is shown in Fig. 3. In 
cases of SLN identification, the total number of sentinel nodes re-
trieved from the surgical specimen was 29, with a mean number 
of 1.6 per patient (range, 1 to 4). On average, a total of 12.7 lymph 
nodes (range, 3 to 31 lymph nodes) were harvested per specimen. 
In three patients, the SLN was the only positive lymph node. In 
three cases (3/19, 15.7%), hot-uptake with direct lymphatic drain-
age was detected outside the perirectal region (251 station) (Fig. 
3B). The mean time between specimen recovery and ex-vivo map-
ping was 45 minutes (range, 15 to 75 minutes). There was one pa-
tient with failed SLN navigation; this patient had a pT3N1 tumor. 
He received neo-adjuvant radiotherapy and underwent an inter-
sphincteric resection with coloanal anastomosis. For that patient, 
seven lymph nodes were harvested with one node metastasis, but 
no SLN was detected.
Histological analyses showed that 10 of 20 patients had lymph 
node metastases. In all but one of those, at least one of the SLNs 
contained tumor cells. In that one patients (false negative case), a 
tumor cell was found in the sigmoid mesenteric node (station 241), 
but the SLN was tumor negative. After additional sectioning and 
staining with pan-cytokeratine, in 2 (20%) of 10 patients with stage 
II rectal cancer (with conventional H&E staining), a micrometas-
tasis (< 2 mm) was found (Fig. 4).
DISCUSSION
Up to 25% of cases without nodal disease still have recurrence 
within 5 years. It is thought that relapse could occur in patients 
who have lymph node metastasis that has not been identified by 
using a standard histological examination. In current nodal stag-
A B
Fig. 2. Sentinel node navigation on the back table. (A) A gamma-radiation probe-guided sentinel node mapping in patients with rectal cancer. 
(B) Bench work at a separate back table to pick up each hot node with radioactivity ten times that of background.Journal of The Korean Society of
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ing, only one or two sections of lymph nodes are selected for his-
topathological evaluation, resulting in a substantial risk of missing 
metastasis in other parts of the lymph node. Additionally, micro-
scopic error, due to a failure of the conventional histopathological 
analysis to detect micrometastasis, may contribute to understag-
ing. If the accuracy of staging in patients with colorectal cancer is 
to be improved, a detailed analysis of lymph nodes recovered from 
the specimen must be performed. Although the oncologic impact 
of micrometastais and the risk of recurrence remain to be defined, 
previous studies have shown that the ultrastaging of lymph nodes 
with multisectioning, immunohistochemical staining or RT-PCT 
identifies a subgroup of pN0 patients with a poorer prognosis [9-
11]. However, it is cost-prohibitive and highly time-consuming to 
ultrastage all the nodes in a given specimen, especially when the 
specimen contains multiple nodes. SLN mapping aims to resolve 
these problems by selecting only a few lymph nodes for detailed 
histopathological analysis.
Fig. 3. Postoperative images in patient with drainage to perirectal 
(station 251) and sigmoid (station 241) lymph nodes. Lymphoscin-
tigraphy 5 hours after injection in patient 13 showed tracer uptake in 
2 sentinel nodes.
Table 1. Clinicopathological characteristics of patients  
No. Age (yr) Sex
BMI  
(kg/m
2)
Surgical 
procedure
Tumor 
height 
(cm)
Pre-OP 
CCRT
  Tumor     
  size 
  (cm)
pTN
a 
stage
Differen-
tiation
Lymphatic 
invasion
Number 
of SLN Location of SLN
  1 67 F 20.4 LAR  9 None 4 T3N1 Moderate None 1 Para-rectal
  2 71 M 23.3 LAR 8 None 5 T3N1 Moderate None 1 Para-rectal
  3 47 F 21.3 uLAR/CAA 9 None    5.5 T3N1 Moderate Yes 1 Para-rectal
  4 59 F 24.2 LAR 8 None    3.5 T3N0 Moderate None 1 Para-rectal
  5 57 M 23.8 LAR 9 None    2.5 T2N0 Moderate None 3 Para-rectal/sigmoid  
mesenteric
  6 68 F 24.5 uLAR/CAA 4 None 1 T1N0 Moderate None 2 Para-rectal/inf. mesenteric trunk
  7 56 M 24.9 LAR 7 None 3 T2N1 Moderate Yes 2 Para-rectal/inf. mesenteric trunk
  8 58 M 24.5 LAR 7 Done    1.5 T3N0 Moderate None 1 Para-rectal
  9 65 M 22.2 uLAR/CAA 3 Done 3 T2N1 Moderate None 2 Para-rectal/inf. mesenteric root
10 68 F 24.2 LAR 9 None 4 T3N1 Moderate None 1 Para-rectal
11 68 M 27.9 LAR   9 None 3 T3N0 Moderate None 1 Para-rectal
12 80 F 19.1 LAR 7 None 4 T3N0 Moderate None 2 Para-rectal/inf. mesenteric trunk
13 60 M 19.6 uLAR/CAA 4 Done 3 T3N0 Moderate Yes 4 Para-rectal/sigmoid node
14 51 M 18.9 LAR 7 None    1.5 T3N2 Moderate None 1 Para-rectal
15 56 F 28.4 LAR   4 Done 4 T2N0 Well None 2 Inf. mesenteric trunk/ 
sigmoid mesenteric
16 63 F 29.4 LAR 8 None    1.5 T1N0 Moderate None 2 Para-rectal/para-rectal
17 60 M 22.1 uLAR/CAA 3 Done 4 T3N1 Poor None 0 Not detected
18 79 F 23.5 uLAR/CAA 3 Done    2.5 T3N2 Moderate None 1 Para-rectal
19 74 F 22.6 LAR 8 None 4 T3N0 Moderate None 1 Para-rectal
20 69 M 24.7 uLAR/CAA 4 Done 1 T3N0 Moderate None 2 Inf. mesenteric trunk/ 
inf. mesenteric root
BMI, body mass index; LPLN, lateral pelvic lymph node; CCRT, combined chemoradiation therapy; LAR, low anterior resection; APR, abdominoperineal resection; CAA, colo 
anal anastomosis; op, operation; SLN, sentinel lymph node.
aReported according to the sixth edition of the AJCC cancer staging. 
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The current pilot study demonstrated the principle that an ex-vivo 
lymphoscintigraphy-guided lymph node mapping can provide an 
acceptable sensitivity and an accurate identification of SLNs in the 
rectum. Although several studies have described successful SLN 
identification in cases of colon cancer, with identification rates of 
94-100% and sensitivities ranging from 85 to 100% [12-14], some 
authors have suggested that the sentinel lymph node mapping tech-
nique might be less applicable for rectal cancer than for colon can-
cer because they found a higher failure rate for detecting SLNs in 
rectal cancer [15, 16]. One of the reasons mentioned is that neo-
adjuvant chemoradiation obliterating the lymphatic channel or 
scleroses lymph nodes of the nodal basin draining the primary 
tumor. A more reasonable explanation might be associated with 
rectal cancer being located in the infraperitoneal region. Injecting 
blue dye into the subserosa within the confined pelvic cavity with-
out leakage and navigating the sentinel lymph node intraopera-
tively during the limited window period (almost 10-20 minutes) 
even after a complete total mesorectal excision are impractical. In 
the present study, the authors could reduce injection failure by in-
jecting the dye through transanal submucosal injection immedi-
ately before the operation so as to exactly inject the dye under di-
rect vision and to use the physiologic lymphatic vessel as effectively 
as possible. We were able to obtain promising sensitivity and ac-
curacy by combining the transanal submucosal injection with the 
back-table work (ex-vivo mapping), which was available for more 
detailed examination than possible with intraoperative navigation.
A detailed pathological work-up of SLNs may increase the diag-
nostic accuracy of the examining pathologist, but it also may stream-
line the tedious process of lymph node evaluation, limiting the num-
ber of lymph nodes examined by considering their qualitative fea-
tures. Accordingly, in accurate SLN-directed staging of colorectal 
cancer, the optimal number of regional lymph nodes to be removed 
remains controversial. According to several previously-published 
clinical studies, the mean number of excised SLNs has been re-
ported to range from 1 to 7 [17-20]. Morton [21] defined the SLN 
as the first lymph node that receives afferent lymphatic drainage 
from a primary tumor, but that definition does not recognize that 
more than a single SLN may be present. In this study, every node 
was considered to be a sentinel node when showing either an ac-
cumulation of radioactive dye on lymphoscintigraphy or ex-vivo 
radioactive counts tenfold higher than background activity in the 
back-table procedures. In our series, the mean window time be-
tween the specimen extraction and an SLN mapping was 45 min-
utes, and the mean number of SLNs was 1.7 per patient (range, 1 
to 4) with a sensitivity of 90%. Presumably, therefore, a mean num-
ber of SLNs of 1.6 might be appropriate not only for identifying 
lymph-node-harboring malignant metastasis but also for avoiding 
an increase in the workload associated with a micrometastasis.
Another valuable benefit of the SLN mapping technique could 
be the ability to recognize aberrant lymphatic drainage, which has 
been reported in 2 to 29% of colorectal cancer cases [22-24]. Study-
ing direct lymphatic drainage from rectal cancer may shed light 
on the unpredictable location of sentinel lymph nodes. In the rad-
ical treatment of rectal cancer, metastasis to the sigmoid mesenteric 
(station 241) and the sigmoid lymph (station 242) nodes should 
be considered as an aberrant metastasis, yet the status of the sig-
moid mesenteric or the sigmoid lymph nodes is not well defined. 
This may be due to the technical difficulties in dissecting or sam-
pling all sigmoid lymph nodes and in mobilizing the splenic flex-
ure. Several studies have reported on the outcome of a J-pouch res-
A
B
HE
× 40
× 400
Cytokeratin CEA
Fig. 4. (A) A micrometastasis 
(circle) disappears in immuno-
histochemistry for cytokeratin 
and carcinoembryonic antigen 
(CEA) in deeper sections. (B) 
Isolated tumor cells (arrows) 
are seen in immunohistoche-
mistry for cytokeratin and CEA, 
but they are not seen in routine 
H&E staining.
Table 2. Results of sentinel lymph node mapping based on injection technique 
No. of cases No. of SLN Detection rate (%) Accuracy (%) Sensitivity (%) False-negative rate (%) Upstaging rate (%)
20 2.3 ± 0.9 19/20 (95.0) 18/19 (94.7) 8/9 (88.8) 1/9 (12.2) 2/10 (20.0)
SLN, sentinel lymph node.Journal of The Korean Society of
Coloproctology
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ervoir using a sigmoid colon segment for an improved functional 
outcome after TME. Of interest, we found that radiocolloid parti-
cles were directly accumulated around the sigmoid mesenteric or 
sigmoid lymph node station in 3 of 19 patients (15.7%). The find-
ings obtained in this study are in agreement with previous find-
ings that not only the root of the inferior mesenteric lymph node, 
but a sizable part of the sigmoid colon with the sigmoid mesenteric 
lymph node should be included in the extent of dissection in the 
subset of patients with rectal cancer [25].
The present study revealed micrometastases or isolated tumor cells 
in the SLNs of 20.0% of patients initially classified as pN0 based 
on a conventional examination. Therefore, our results confirm the 
findings of early studies using SLN mapping [7, 20, 26]. However, 
these results did not influence adjuvant treatment decisions in our 
clinical setting. Lymphatic mapping in the present trial was consid-
ered investigational, and our oncologists performed adjuvant treat-
ment according to conventional guidelines. Until now, the influ-
ence of lymphatic micrometastases on cancer prognosis has not 
been clearly established. Although some studies have shown that 
micrometastases can adversely affect disease outcomes, several 
other studies have been unable to show such a correlation. A re-
cent multicenter trial that represents the first prospective evalua-
tion of the prognostic impact of micrometastases detected a direct 
correlation between the presence of a micrometastasis and disease-
free survival [12]. However, further additional, randomized, pro-
spective trials and long-term follow-up studies are warranted to 
assess the prognostic value of ultrastaging. This is because the fol-
low ups in the previous literature were relatively short and because 
evidence supporting the trend for administration of adjuvant che-
motherapy to patients with micrometastasis exists.
The strengths of this study include the whole evaluation of mi-
crometastasis in both SLNs and non-SLNs. The complete analysis 
made it possible to assess the actual upstaging rates and false neg-
ative rates. The main limitation of the study is the mixed cohorts, 
including preoperative chemoradiation and non-radiation subsets. 
Further study with a homogeneous study group is needed, taking 
into consideration the impact of preoperative radiation on the lym-
phatic pathway. The relatively low rectal location of the target le-
sion is another drawback of the current study. We mainly have to 
deal with extraperitoneal tumors due to injection with a transanal 
approach under direct vision. An evaluation of an endoscopic map-
ping protocol of procedures that integrates preoperative tattooing 
and dye injection via colonoscopy is now in progress so that it can 
be reported in the future.
In conclusion, SLN identification and sampling after preoperative 
transanal injection with detection on lymphoscintigraphy is surgi-
cally feasible and safe in patients with extraperitoneal rectal cancer. 
Preliminary data suggest that SLNs from the rectal cancer are mainly 
localized in the pararectal region, but aberrant nodes receiving di-
rect drainage from the rectal cancer had developed in 15.7% of the 
cases. To draw more conclusive scientific conclusions, we must 
wait to increase the number of cases submitted to this procedure 
protocol and to increase the duration of follow-up evaluation.
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